SEC Form 4 · accession 0001579629-26-000004
Cue Biopharma, Inc. · CUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sumita Ray
Officer — Chief Legal Compliance Officer · Other
Period of report
Jul 9, 2026
Accepted (ET)
Jul 10, 2026 · 7:33 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001645460
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 9, 2026 | A | 54,589 | $0.00 | A | 109,178 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF2 | — | Jul 9, 2026 | A | 54,589 | A | — | — | Common Stock | 54,589 | 54,589 | D |
Explanation of responses
- F1Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.
- F2Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.